Abstract
Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.
| Original language | English |
|---|---|
| Pages (from-to) | 19-30 |
| Number of pages | 12 |
| Journal | Journal of Mammary Gland Biology and Neoplasia |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2003 |
Fingerprint
Keywords
- Breast neoplasms
- Chemoprevention
- Clinical trial
- Fenretinide
- Retinoids
ASJC Scopus subject areas
- Cancer Research
Cite this
Breast Cancer Prevention Trials Using Retinoids. / Decensi, Andrea; Serrano, Davide; Bonanni, Bernardo; Cazzaniga, Massimiliano; Guerrieri-Gonzaga, Aliana.
In: Journal of Mammary Gland Biology and Neoplasia, Vol. 8, No. 1, 01.2003, p. 19-30.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Breast Cancer Prevention Trials Using Retinoids
AU - Decensi, Andrea
AU - Serrano, Davide
AU - Bonanni, Bernardo
AU - Cazzaniga, Massimiliano
AU - Guerrieri-Gonzaga, Aliana
PY - 2003/1
Y1 - 2003/1
N2 - Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.
AB - Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.
KW - Breast neoplasms
KW - Chemoprevention
KW - Clinical trial
KW - Fenretinide
KW - Retinoids
UR - http://www.scopus.com/inward/record.url?scp=1642441732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642441732&partnerID=8YFLogxK
U2 - 10.1023/A:1025779120649
DO - 10.1023/A:1025779120649
M3 - Article
C2 - 14587861
AN - SCOPUS:1642441732
VL - 8
SP - 19
EP - 30
JO - Journal of Mammary Gland Biology and Neoplasia
JF - Journal of Mammary Gland Biology and Neoplasia
SN - 1083-3021
IS - 1
ER -